Literature DB >> 3922505

Intranasal calcitonin and plasma calcium concentrations in normal subjects.

A E Pontiroli, M Alberetto, G Pozza.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3922505      PMCID： PMC1415597          DOI： 10.1136/bmj.290.6479.1390

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  4 in total

1.  EFFECTIVENESS OF PER-ORAL INSULIN IN HUMAN DIABETES.

Authors:  J R Murlin; C B Gibbs; M J Romansky; T B Steinhausen; F L Truax
Journal:  J Clin Invest       Date:  1940-09       Impact factor: 14.808

2.  Comparison of plasma levels of luteinizing hormone releasing hormone in men after intravenous or intranasal administration.

Authors:  G Fink; G Gennser; P Liedholm; J Thorell; J Mulder
Journal:  J Endocrinol       Date:  1974-11       Impact factor: 4.286

3.  Intranasal glucagon raises blood glucose concentrations in healthy volunteers.

Authors:  A E Pontiroli; M Alberetto; G Pozza
Journal:  Br Med J (Clin Res Ed)       Date:  1983-08-13

4.  Insulin given intranasally induces hypoglycaemia in normal and diabetic subjects.

Authors:  A E Pontiroli; M Alberetto; A Secchi; G Dossi; I Bosi; G Pozza
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-30
  4 in total
  11 in total

1.  Intranasal and intramuscular human calcitonin in female osteoporosis and in Paget's disease of bones: a pilot study.

Authors:  A E Pontiroli; E Pajetta; A Calderara; M Alberetto; G Pozza; V Manganelli; G Resmini; L Tessari; V Maresca
Journal:  J Endocrinol Invest       Date:  1991-01       Impact factor: 4.256

2.  The use of nasal calcitonin spray in the treatment of hypercalcaemia of malignancy.

Authors:  M Bower; R C Stein; A Hedley; J Davenport; K Colston; R C Coombes
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  The effect of different doses of nasal salmon calcitonin on plasma cyclic AMP and serum ionized calcium.

Authors:  G Thamsborg; T L Storm; E Brinch; R Sykulski; N Fogh-Andersen; S N Holmegaard; O H Sørensen
Journal:  Calcif Tissue Int       Date:  1990-01       Impact factor: 4.333

Review 4.  Intranasal drug delivery. Potential advantages and limitations from a clinical pharmacokinetic perspective.

Authors:  A E Pontiroli; A Calderara; G Pozza
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

5.  Effect of different doses of nasal salmon calcitonin on bone mass.

Authors:  G Thamsborg; T L Storm; R Sykulski; E Brinch; H K Nielsen; O H Sørensen
Journal:  Calcif Tissue Int       Date:  1991-05       Impact factor: 4.333

6.  Intranasal absorption of salmon calcitonin.

Authors:  H Kurose; Y Seino; M Shima; H Tanaka; M Ishida; K Yamaoka; H Yabuuchi
Journal:  Calcif Tissue Int       Date:  1987-11       Impact factor: 4.333

7.  Acute effects of nasal salmon calcitonin on calcium and bone metabolism.

Authors:  G Thamsborg; S G Skousgaard; H Daugaard; S Schifter; G Kollerup; O H Sørensen
Journal:  Calcif Tissue Int       Date:  1993-10       Impact factor: 4.333

8.  Effect of organogel components on in vitro nasal delivery of propranolol hydrochloride.

Authors:  Sambhaji Pisal; Vijay Shelke; Kakasaheb Mahadik; Shivajirao Kadam
Journal:  AAPS PharmSciTech       Date:  2004-09-13       Impact factor: 3.246

Review 9.  Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging.

Authors:  S P Clissold; A Fitton; P Chrisp
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923

10.  Recent developments in peptide-based nucleic acid delivery.

Authors:  Sandra Veldhoen; Sandra D Laufer; Tobias Restle
Journal:  Int J Mol Sci       Date:  2008-07-16       Impact factor: 6.208
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.